Psychedelic Vouchers Show How FDA's National Priority Voucher Pilot Works

The Food and Drug Administration said on April 24 that it is issuing national priority vouchers to three companies developing psychedelic drugs: psilocybin for treatment-resistant depression, psilocybin for major depressive disorder and methylone for post-traumatic stress disorder. The announcement, which did not name the companies, followed an April 18 executive order directing the Department of Health and Human Services to accelerate access to treatments for serious mental illness.

The same day FDA allowed an early-phase study of noribogaine hydrochloride for alcohol use disorder to proceed under an investigational new drug application, which it called the first U.S. clinical study it has allowed of a derivative of ibogaine. FDA added that the decision "does not mean the drug has been approved or found to be safe or effective."

The vouchers are the newest awards under a program FDA has run for less than a year.

What the voucher buys

FDA's program page says the Commissioner's National Priority Voucher pilot, announced in June 2025, is meant to sharply cut review times for drug and biological product applications and for manufacturing or efficacy supplements. Products must align with one of five national priorities: public health crisis response, innovative therapies with novel mechanisms, large unmet medical needs, onshoring of drug development and manufacturing, and affordability.

The benefits are enhanced communication with FDA and rolling review. The page contrasts a target timeline of one to two months with "6+ months" for other priority review programs. FDA's program FAQ describes the targets as a pre-submission period of about 60 days, an abbreviated filing period to check that the application is complete, and a review period of about one to two months. Sponsors must send manufacturing data, draft labeling and a list of facilities and study sites at least 60 days before the full application, or 120 days if foreign inspections are expected.

A voucher can be granted at any stage of development; one given during the investigational phase brings more frequent interactions with FDA while the product is still being studied. FDA expects the voucher process to be started generally within two years of issuance. Vouchers cannot be transferred to another company, though they stay valid through changes in ownership. The pilot covers drugs, biologics and certain combination products.

What it does not change

FDA says applications selected for the pilot are subject to the same statutory and regulatory requirements for approval as any other. Each is reviewed by the usual review team in the relevant center, which shares its recommendations with a multidisciplinary panel, now called the CNPV Review Council, in what FDA calls a "tumor board-style" discussion. The FAQ says that council does not make approval decisions; it makes a non-binding recommendation to the center director, and the decision follows the center's normal processes.

The pilot also sits alongside existing programs rather than replacing them. FDA says priority review and the separate priority review voucher programs continue unchanged, and fast track, breakthrough therapy designation and accelerated approval are not affected. A voucher holder can still receive accelerated approval if its product meets the legal requirements.

How vouchers are awarded

Companies may submit a statement of interest through FDA's website, and FDA review divisions may nominate applications already under review. Selection criteria and the council's role are set out in a Staff Manual Guide that FDA has published. The program page lists voucher awards beginning in October 2025, when nine sponsors received the first vouchers, and approvals beginning in December 2025.

FDA said in its FAQ that it intends to seek public feedback through a Federal Register notice and to issue draft guidance as the program matures. For the three psychedelic programs, the April 24 announcement said FDA also intends to release final guidance on designing clinical trials of serotonin-2A agonists and related products.